We are live on ! Find out more
SCM

Suvretta Capital Management Portfolio holdings

AUM $3.92B
1-Year Est. Return 86.67%
This Fund
S&P 500
This Quarter Est. Return
-5.34%
1 Year Est. Return
+86.67%
3 Year Est. Return
+295.96%
5 Year Est. Return
+364.48%
10 Year Est. Return
+2,073.65%
AUM
$3.27B
AUM Growth
-$1.89B
Cap. Flow
-$1.48B
Cap. Flow %
-45.31%
Top 10 Hldgs %
36.77%
Holding
111
New
16
Increased
19
Reduced
19
Closed
24

Top Buys

Rank Stock Value
1
CNC icon
Centene
CNC
+$98.2M
2
V icon
Visa
V
+$94.7M
3
LVS icon
Las Vegas Sands
LVS
+$94.4M
4
SCHW
Charles Schwab
SCHW
+$86.5M
5
SPGI icon
S&P Global
SPGI
+$84.2M

Top Sells

Rank Stock Value
1
ADBE icon
Adobe
ADBE
+$222M
2
AMZN icon
Amazon
AMZN
+$194M
3
ADI icon
Analog Devices
ADI
+$144M
4
PWR icon
Quanta Services
PWR
+$133M
5
COR icon
Cencora
COR
+$122M

Sector Composition

Rank Sector Weight
1 Healthcare 47.04%
2 Consumer Discretionary 18.58%
3 Financials 10.68%
4 Industrials 10.44%
5 Technology 6.98%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PHVS icon
51
Pharvaris
PHVS
$2.44B
$15M 0.46%
827,540
– –
CMRX
52
DELISTED
Chimerix, Inc.
CMRX
$12.7M 0.39%
2,766,619
– –
MREO
53
Mereo BioPharma
MREO
$47.3M
$10.2M 0.31%
9,142,067
– –
SYRE icon
54
Spyre Therapeutics
SYRE
$9.25B
$9.34M 0.29%
162,396
+59,556
+58% +$5M
SLDB icon
55
Solid Biosciences
SLDB
$900M
$8.67M 0.26%
481,657
+62,511
+15% +$1.1M
MOLN
56
Molecular Partners
MOLN
$152M
$8.22M 0.25%
400,000
– –
OTIC
57
DELISTED
Otonomy, Inc.
OTIC
$7.55M 0.23%
3,144,196
+466,081
+17% +$991K
BHVN
58
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$7.31M 0.22%
+61,631
New +$7.69M
IOVA icon
59
Iovance Biotherapeutics
IOVA
$2.87B
$6.76M 0.21%
+406,200
New +$6.28M
AMAM
60
DELISTED
Ambrx Biopharma Inc
AMAM
$6.15M 0.19%
1,491,832
+434,097
+41% +$2.22M
BOLT icon
61
Bolt Biotherapeutics
BOLT
$7.78M
$6.11M 0.19%
111,513
– –
IFRX icon
62
InflaRx
IFRX
$271M
$6.01M 0.18%
3,285,000
– –
RACB
63
DELISTED
Research Alliance Corp. II Class A Common Stock
RACB
$4.88M 0.15%
500,000
– –
AUPH icon
64
Aurinia Pharmaceuticals
AUPH
$2.11B
$4.27M 0.13%
+344,755
New +$5.33M
INZY
65
DELISTED
Inozyme Pharma
INZY
$4.14M 0.13%
1,013,216
– –
SIOX
66
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$3.96M 0.12%
5,914,000
– –
TERN
67
DELISTED
Terns Pharmaceuticals
TERN
$3.68M 0.11%
1,238,800
– –
ROIV icon
68
Roivant Sciences
ROIV
$26.2B
$3.37M 0.1%
681,528
– –
IRON icon
69
Disc Medicine
IRON
$2.97B
$3.3M 0.1%
79,076
– –
OMEG
70
DELISTED
Omega Alpha SPAC Class A Ordinary Shares
OMEG
$2.95M 0.09%
300,000
– –
EBAC
71
DELISTED
European Biotech Acquisition Corp. Class A Ordinary Shares
EBAC
$2.92M 0.09%
300,000
– –
ORIC icon
72
Oric Pharmaceuticals
ORIC
$1.4B
$2.35M 0.07%
440,696
– –
OHAAU
73
DELISTED
OPY Acquisition Corp. I Units
OHAAU
$2M 0.06%
200,000
– –
BLSA
74
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$1.97M 0.06%
200,000
– –
TMPM
75
DELISTED
Turmeric Acquisition Corp. Class A Ordinary Shares
TMPM
$1.97M 0.06%
200,000
– –
1 2
3
4 5

Similar funds

MIM
Meridiem Investment Management London, United Kingdom $3.92B AUM 1.64% 1-Year Est. Return
BCP
BSN Capital Partners London, United Kingdom $3.93B AUM 13.09% 1-Year Est. Return
AS
American Securities New York $3.93B AUM 52.22% 1-Year Est. Return
MSI
Mitsui Sumitomo Insurance Tokyo, Japan $3.9B AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
LWCA
Locust Wood Capital Advisers New York $3.95B AUM 33.1% 1-Year Est. Return
TFM
Trian Fund Management New York $3.86B AUM 26.59% 1-Year Est. Return
USCWA
U.S. Capital Wealth Advisors Austin, Texas $3.98B AUM 22.36% 1-Year Est. Return

Suvretta Capital Management's Q1 2022 Portfolio in Review

As of Q1 2022, Suvretta Capital Management held 111 positions worth $3.27B, down 37% from $5.16B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Suvretta Capital Management withdrew a net $1.48B in Q1 2022, closing 24 positions and reducing 19 holdings. Its most notable exit was Adobe, an estimated $222M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 47% of assets, up from 35% a quarter earlier, followed by Consumer Discretionary and Financials.

Against the trend, Suvretta Capital Management opened a new position in Centene worth $101M.

  • Suvretta Capital Management's largest Q1 2022 buy was Centene: 1,197,206 shares worth $101M.
  • Suvretta Capital Management added most to Marqeta in Q1 2022, an estimated $30M increase.
  • Suvretta Capital Management's biggest Q1 2022 reduction was Amazon, cutting an estimated $194M.
  • Suvretta Capital Management fully exited Adobe in Q1 2022, selling an estimated $222M.
  • Suvretta Capital Management's ten largest holdings make up 37% of its $3.27B portfolio in Q1 2022.
  • Suvretta Capital Management opened 16 new positions and closed 24 in Q1 2022.
  • Suvretta Capital Management's portfolio value fell 37% quarter-over-quarter to $3.27B.

Based on Suvretta Capital Management's 13F filing for Q1 2022, filed 16 May 2022.